Trial Profile

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimavanserin (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Sponsors Acadia Pharmaceuticals

Most Recent Events

31 Aug 2022 Status changed from active, no longer recruiting to completed.
23 Dec 2021 Planned End Date changed from 1 Mar 2022 to 1 May 2022.
23 Dec 2021 Planned primary completion date changed from 1 Feb 2022 to 26 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com